Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 5/20 | 0.56 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2622390 | 0.86 | AGPAT2 (0.62) | AGPAT2CDK9APPNR1I2AHR | |
| SCHEMBL4373020 | 0.84 | AGPAT2 (0.77) | AGPAT2CDK9APPNR1I2AHR | |
| SCHEMBL4368518 | 0.83 | AGPAT2 (0.56) | AGPAT2CDK9APPNR1I2AHR | |
| SCHEMBL18269844 | 0.81 | AGPAT2 (0.57) | AGPAT2CDK9APPNR1I2AHR | |
| SCHEMBL4369191 | 0.81 | AGPAT2 (0.54) | AGPAT2CDK9APPNR1I2AHR | |
| SCHEMBL14367207 | 0.79 | AGPAT2 (0.54) | AGPAT2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL13622471 | 0.78 | AGPAT2 (0.53) | AGPAT2CDK9APPNR1I2AHR | |
| SCHEMBL4539786 | 0.77 | AGPAT2 (0.60) | AGPAT2CDK9HTTPOLBCYP1A2 | |
| SCHEMBL4361915 | 0.76 | AGPAT2 (0.85) | AGPAT2CDK9HTTCYP1A2CYP3A4 | |
| SCHEMBL2622392 | 0.75 | AGPAT2 (0.58) | AGPAT2CDK9APPHTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158677-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | AGPAT2 1226/4885CDK9 1410/4885APP 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.